{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T07:49:09Z","timestamp":1775461749622,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-025-04818-0","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:53:29Z","timestamp":1764320009000},"page":"6849-6859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety profile of olanzapine\/samidorphan: focus on metabolic risks, opioid-related effects, and novel adverse events identified"],"prefix":"10.1007","volume":"399","author":[{"given":"Xiangyu","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingjing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiandi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"4818_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12991-015-0075-x","volume":"14","author":"SG Anderson","year":"2015","unstructured":"Anderson SG, Livingston M, Couchman L et al (2015) Sex differences in plasma clozapine and norclozapine concentrations in clinical practice and in relation to body mass index and plasma glucose concentrations: a retrospective survey. Ann Gen Psychiatry 14:39","journal-title":"Ann Gen Psychiatry"},{"key":"4818_CR2","unstructured":"Centers for Disease Control and Prevention (CDC) (2013) Deaths and severe adverse events associated with anesthesia-assisted rapid opioid detoxification--New York City, 2012. MMWR Morb Mortal Wkly Rep 62(38):777\u2013780"},{"key":"4818_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107498","volume":"95","author":"C Chen","year":"2021","unstructured":"Chen C, Wu B, Zhang C et al (2021) Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int Immunopharmacol 95:107498","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"4818_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40263-022-00923-3","volume":"36","author":"MM Corrao","year":"2022","unstructured":"Corrao MM, Nelson LA (2022) Olanzapine\/samidorphan: a new combination treatment for schizophrenia and bipolar I disorder intended to reduce weight gain. CNS Drugs 36(6):605\u2013616","journal-title":"CNS Drugs"},{"issue":"10","key":"4818_CR5","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1177\/0269881119856850","volume":"33","author":"JI Cunningham","year":"2019","unstructured":"Cunningham JI, Eyerman DJ, Todtenkopf MS et al (2019) Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates. J Psychopharmacol 33(10):1303\u20131316","journal-title":"J Psychopharmacol"},{"issue":"2","key":"4818_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrendo.2011.156","volume":"8","author":"M De Hert","year":"2011","unstructured":"De Hert M, Detraux J, van Winkel R et al (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8(2):114\u2013126","journal-title":"Nat Rev Endocrinol"},{"key":"4818_CR7","doi-asserted-by":"publisher","first-page":"1101861","DOI":"10.3389\/fphar.2023.1101861","volume":"14","author":"Z Fang","year":"2023","unstructured":"Fang Z, Xu Z, Zhu W et al (2023) A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system. Front Pharmacol 14:1101861","journal-title":"Front Pharmacol"},{"issue":"9","key":"4818_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/NMD.0b013e3182a2168a","volume":"201","author":"MB First","year":"2013","unstructured":"First MB (2013) Diagnostic and statistical manual of mental disorders, 5th edition, and clinical utility. J Nerv Ment Dis 201(9):727\u2013729","journal-title":"J Nerv Ment Dis"},{"issue":"8","key":"4818_CR9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2024.2368817","volume":"23","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Raschi E, Poluzzi E et al (2024) The evolving role of disproportionality analysis in pharmacovigilance. Expert Opin Drug Saf 23(8):981\u2013994","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"4818_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/clpt.1993.104","volume":"54","author":"SE Gaudry","year":"1993","unstructured":"Gaudry SE, Sitar DS, Smyth DD et al (1993) Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. Clin Pharmacol Ther 54(1):23\u201327","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"4818_CR11","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1111\/bcp.15802","volume":"89","author":"CA Gravel","year":"2023","unstructured":"Gravel CA, Douros A (2023) Considerations on the use of different comparators in pharmacovigilance: a methodological review. Br J Clin Pharmacol 89(9):2671\u20132676","journal-title":"Br J Clin Pharmacol"},{"issue":"10323","key":"4818_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","volume":"399","author":"S Jauhar","year":"2022","unstructured":"Jauhar S, Johnstone M, McKenna PJ (2022) Schizophrenia. Lancet 399(10323):473\u2013486","journal-title":"Lancet"},{"key":"4818_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.schres.2021.04.009","volume":"232","author":"RS Kahn","year":"2021","unstructured":"Kahn RS, Silverman BL, DiPetrillo L et al (2021) A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: results from the ENLIGHTEN-2 long-term extension. Schizophr Res 232:45\u201353","journal-title":"Schizophr Res"},{"key":"4818_CR14","doi-asserted-by":"crossref","unstructured":"Kraal AZ, Ward KM, Ellingrod VL (2017) Sex differences in antipsychotic related metabolic functioning in schizophrenia spectrum disorders. Psychopharmacol Bull. 47(2)","DOI":"10.64719\/pb.4358"},{"issue":"8","key":"4818_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1177\/02698811251337374","volume":"39","author":"K Lee","year":"2025","unstructured":"Lee K, Twohig M, Idoko NP, Williams BD (2025) Centrally-acting opioid receptor antagonists as a treatment for antipsychotic-induced weight gain: a systematic review and meta-analysis of clinical trial data. J Psychopharmacol 39(8):790\u2013803","journal-title":"J Psychopharmacol"},{"key":"4818_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jad.2024.03.085","volume":"354","author":"R Lu","year":"2024","unstructured":"Lu R, Jiang Y, Du Z et al (2024) Multidimensional assessment of adverse events of bupropion: a large-scale data analysis from the FAERS database. J Affect Disord 354:649\u2013655","journal-title":"J Affect Disord"},{"issue":"3","key":"4818_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1017\/S1092852912001010","volume":"18","author":"D Marazziti","year":"2013","unstructured":"Marazziti D, Baroni S, Picchetti M et al (2013) Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex. CNS Spectr 18(3):118\u2013127","journal-title":"CNS Spectr"},{"issue":"9","key":"4818_CR18","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1177\/10600280211070330","volume":"56","author":"C Monahan","year":"2022","unstructured":"Monahan C, McCoy L, Powell J et al (2022) Olanzapine\/samidorphan: new drug approved for treating bipolar I disorder and schizophrenia. Ann Pharmacother 56(9):1049\u20131057","journal-title":"Ann Pharmacother"},{"key":"4818_CR19","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12769","author":"SG Potkin","year":"2020","unstructured":"Potkin SG, Kunovac J, Silverman BL et al (2020) Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, phase 3 ENLIGHTEN-1 study. J Clin Psychiatry. https:\/\/doi.org\/10.4088\/JCP.19m12769","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"4818_CR20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/0706743717720448","volume":"62","author":"G Remington","year":"2017","unstructured":"Remington G, Addington D, Honer W et al (2017) Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry 62(9):604\u2013616","journal-title":"Can J Psychiatry"},{"issue":"3","key":"4818_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.euroneuro.2018.01.004","volume":"28","author":"G Scaini","year":"2018","unstructured":"Scaini G, Quevedo J, Velligan D et al (2018) Second generation antipsychotic-induced mitochondrial alterations: implications for increased risk of metabolic syndrome in patients with schizophrenia. Eur Neuropsychopharmacol 28(3):369\u2013380","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"4818_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/JCP.0000000000000320","volume":"35","author":"MJ Shram","year":"2015","unstructured":"Shram MJ, Silverman B, Ehrich E et al (2015) Use of remifentanil in a novel clinical paradigm to characterize onset and duration of opioid blockade by samidorphan, a potent \u03bc-receptor antagonist. J Clin Psychopharmacol 35(3):242\u2013249","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"4818_CR23","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1002\/cam4.5062","volume":"12","author":"Y Shu","year":"2023","unstructured":"Shu Y, Ding Y, He X et al (2023) Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database. Cancer Med 12(3):3365\u20133375","journal-title":"Cancer Med"},{"key":"4818_CR24","volume":"2011","author":"OP Soldin","year":"2011","unstructured":"Soldin OP, Chung SH, Mattison DR (2011) Sex differences in drug disposition. J Biomed Biotechnol 2011:187103","journal-title":"J Biomed Biotechnol"},{"issue":"12","key":"4818_CR25","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","volume":"28","author":"M Solmi","year":"2023","unstructured":"Solmi M, Seitidis G, Mavridis D et al (2023) Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Mol Psychiatry 28(12):5319\u20135327","journal-title":"Mol Psychiatry"},{"issue":"2","key":"4818_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/14740338.2023.2248873","volume":"23","author":"E Stamoula","year":"2024","unstructured":"Stamoula E, Stamatellos V-P, Vavilis T et al (2024) Weight gain, gender, and antipsychotics: a disproportionality analysis of the FDA adverse event reporting system database (FAERS). Expert Opin Drug Saf 23(2):239\u2013245","journal-title":"Expert Opin Drug Saf"},{"key":"4818_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2020.109881","volume":"100","author":"L Sun","year":"2020","unstructured":"Sun L, Yagoda S, Xue H et al (2020) Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: results from a phase 1 QT\/QTc study. Prog Neuropsychopharmacol Biol Psychiatry 100:109881","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"4818_CR28","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bdi.13135","volume":"23","author":"L Yatham","year":"2021","unstructured":"Yatham L, Chakrabarty T, Bond D et al (2021) Canadian network for mood and anxiety treatments (CANMAT) and International society for bipolar disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disord 23:767\u2013788","journal-title":"Bipolar Disord"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04818-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04818-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04818-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:51:45Z","timestamp":1775458305000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04818-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4818"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04818-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not require ethical approval and consent to participate to use the publicly available and anonymized datasets from the FAERS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}